A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer




TekijätEurola Annika, Ristimäki Ari, Mustonen Harri, Nurmi Anna-Maria, Hagström Jaana, Haglund Caj, Seppänen Hanna

KustantajaNature Publishing Group

Julkaisuvuosi2021

JournalScientific Reports

Tietokannassa oleva lehden nimiScientific reports

Lehden akronyymiSci Rep

Artikkelin numero9896

Vuosikerta11

Numero1

ISSN2045-2322

eISSN2045-2322

DOIhttps://doi.org/10.1038/s41598-021-89134-2

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/58940947


Tiivistelmä
Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six-tier grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. Strong podocalyxin immunopositivity associated with poor survival in the patients responding poorly to the neoadjuvant treatment (HR 4.16, 95% CI 1.56-11.01, p = 0.004), although neoadjuvant patients exhibited generally low podocalyxin expression (p = 0.017). Strong podocalyxin expression associated with perineural invasion (p = 0.003) and lack of radiation (p = 0.036). Two patients exhibited a complete neoadjuvant response, while a strong neoadjuvant response (≤ 5% of residual tumor cells) significantly associated with lower stage, pT-class and grade, less spread to the regional lymph nodes, less perineural invasion, and podocalyxin negativity (p < 0.05, respectively). A strong response predicted better survival (HR 0.28, 95% CI 0.09-0.94, p = 0.039). In conclusion, strong podocalyxin expression associates with poor survival among poorly responding neoadjuvant patients. A good response associates with podocalyxin negativity. A strong response associates with better outcome.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 15:19